GlassScriptPhysician profile
Ariana D Buchanan
NPI 1922026525
$3,787.31
in general payments reported to CMS, 2019-2025
25 companies · $820 in 2025
The $820 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.56 · 2020: $138 · 2021: $640 · 2022: $672 · 2023: $822 · 2024: $672 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Education: $57.48 · Consulting Fee: $36.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.36 |
| Education | $57.48 |
| Consulting Fee | $36.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $650.53 | 2020-2025 | Cuvitru, Hyqvia |
| Genzyme Corporation | $481.07 | 2022-2025 | |
| Glaxosmithkline, LLC. | $442.65 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $231.15 | 2021-2025 | Xembify |
| Astrazeneca Pharmaceuticals LP | $227.22 | 2021-2025 | Fasenra, Tezspire |
| Novartis Pharmaceuticals Corporation | $216.98 | 2019-2025 | |
| Tersera Therapeutics LLC | $202.52 | 2023-2025 | Quzyttir |
| Biocryst US Sales Co., LLC | $201.27 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $154.12 | 2021-2024 | Ayvakit |
| Amgen INC. | $122.15 | 2024-2025 | Tezspire |
| Pfizer INC. | $108.33 | 2021-2025 | |
| Pharming Healthcare, INC. | $103.94 | 2022-2025 | Ruconest |
| Optinose US, INC. | $79.93 | 2021-2022 | |
| Incyte Corporation | $71.80 | 2023-2024 | Opzelura |
| Kaleo, INC. | $69.38 | 2020-2023 | Auvi-Q |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.71 | 2021-2022 | |
| Adma Biomanufacturing LLC | $62.08 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Alk-Abello, INC | $52.82 | 2022 | |
| Csl Behring | $47.95 | 2022-2023 | Hizentra |
| Octapharma USA, INC. | $47.76 | 2021 | |
| Ionis Pharmaceuticals, INC. | $26.65 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $24.61 | 2021 | |
| Leo Pharma INC. | $20.07 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.14 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariana Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.